BTIG analyst Marie Thibault raised the firm’s price target on Edwards Lifesciences (EW) to $103 from $100 and keeps a Buy rating on the shares. The are plenty of catalysts in 2026, with potential NCD, guideline updates, and launches fueling outyears acceleration, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences: Strategic Initiatives and Promising Developments Drive Raised Price Target
- Edwards Lifesciences: A Strong Growth Opportunity in Medtech with Expanding Market Potential and Robust Product Portfolio
- Edwards Lifesciences backs FY25 EPS view $2.56-$2.62, consensus $2.59
- Edwards Lifesciences sees FY26 adjusted EPS $2.80-$2.95, consensus $2.86
- Promising Outlook for Edwards Lifesciences: TAVR Expansion and Strong Growth Prospects Drive Buy Rating